Topical therapy for symptom control in chronic polypous rhinosinusitis
Meditsinskiy sovet = Medical Council · 05.06.2026 · (6) · 104-111
DOI: 10.21518/ms2026-116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 05.06.2026. Verfasst von T. Yu. Vladimirova und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Introduction
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a pressing problem in modern otolaryngology.
Aim
To evaluate the efficacy of mometasone furoate in symptom control in patients with newly diagnosed CRSwNP. Materials and methods . The sample included 66 patients aged 18 to 60 years (mean age 45.6 ± 12.6 years) with newly diagnosed CRSwNP. All patients received mometasone furoate monotherapy, two sprays (100 mcg) in each nasal passage twice daily for 30 days. The efficacy of the treatment was assessed dynamically over 6 months using the SNOT-22 and QOD-NS questionnaires. The SST-12 test was used to assess olfactory function, and respiratory function was assessed using anterior active rhinomanometry (AAR).
Results
During the dynamic observation, a decrease in the average total score on the SNOT-22 questionnaire was revealed from the beginning of therapy with mometasone furoate (45.0 ± 14.1 points) to the end of the treatment course (10.0 ± 5.1 points, p < 0.001). Already by the 14th day, regression of severe complaints of nasal congestion and nasal discharge was noted; the overwhelming majority of patients noted this complaint as mild – 30.3% and 37.9% of patients, respectively. By the end of the course (day 30), nasal congestion was absent in 45.5% of patients, and nasal discharge stopped in 44.9% of patients. Self-assessment of the severity of sinonasal symptoms was confirmed by AAR data (p < 0.001). The complaint of «decreased sense of smell/taste» showed the most significant improvement by the first month of observation: 57.6% of patients reported no decrease in sense of smell/taste, while 25.8% rated it as mild.
Conclusion
In patients with newly diagnosed CRSwNP, administration of intranasal topical mometasone furoate as monotherapy for one month significantly improved quality of life and controlled the main symptoms of the disease.
Zitieren
APA
Vladimirova, T. Y., Svistushkin, V. M., Martynova, A. B., & Blashentsev, M. K. (2026). Topical therapy for symptom control in chronic polypous rhinosinusitis. Meditsinskiy sovet = Medical Council, 104-111. https://doi.org/10.21518/ms2026-116
Vancouver
Vladimirova TY, Svistushkin VM, Martynova AB, Blashentsev MK. Topical therapy for symptom control in chronic polypous rhinosinusitis. Meditsinskiy sovet = Medical Council. 2026:104-111. doi:10.21518/ms2026-116
BibTeX
@article{Vladimirova2026,
author = {Vladimirova, T. Yu. and Svistushkin, V. M. and Martynova, A. B. and Blashentsev, M. K.},
title = {Topical therapy for symptom control in chronic polypous rhinosinusitis},
journal = {Meditsinskiy sovet = Medical Council},
year = {2026},
number = {6},
pages = {104--111},
doi = {10.21518/ms2026-116}
}
EUVIMED